Skip to main content

Table 2 Multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall mortality, breast cancer mortality, and recurrence in basic models (adjusted for study and treatment regimen only)

From: Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

   Overall mortality Breast cancer mortality Recurrence
Variable Number Events HRa 95% CI P-value Events HR 95% CI P-value Events HR 95% CI P-value
Body mass index, k/m 2              
<18.5 66 11 1.08 0.59, 1.98 0.796 9 1.06 0.54, 2.06 0.864 12 0.88 0.49, 1.56 0.650
18.5 to 24.9 2,297 312 1.00    256 1.00    419 1.00   
25.0 to 29.9 1,944 265 0.99 0.84, 1.16 0.880 220 1.00 0.83, 1.20 0.984 348 0.95 0.83, 1.10 0.522
30.0 to 34.9 945 139 1.07 0.87, 1.30 0.526 111 1.04 0.83, 1.29 0.757 173 0.98 0.82, 1.17 0.831
≥35.0 431 91 1.47 1.16, 1.85 0.001 68 1.32 1.01, 1.72 0.043 95 1.14 0.91, 1.42 0.249
     P for trend 0.002    P for trend 0.074    P for trend 0.287
Age at diagnosis, years              
23 to 44 1,667 276 1.00    245 1.00    416 1.00   
45 to 54 2,036 228 0.66 0.55, 0.78 <0.001 187 0.61 0.50, 0.73 <0.001 296 0.54 0.47. 0.63 <0.001
55 to 64 1,443 202 0.92 0.77, 1.11 0.380 156 0.81 0.66, 0.99 0.036 231 0.66 0.56, 0.78 <0.001
65 to 76 537 112 1.41 1.13, 1.76 0.002 76 1.08 0.83, 1.39 0.583 104 0.81 0.65, 1.00 0.049
     P for trend 0.030    P for trend 0.655    P for trend <0.001
Menopausal status              
Postmenopausal 2,661 421 1.00    322 1.00    461 1.00   
Premenopausal 3022 397 0.75 0.66, 0.86 <0.001 342 0.85 0.73, 0.98 0.031 586 1.05 0.93, 1.19 0.415
Histology              
Ductal 4,809 700 1.00    571 1.00    892 1.00   
Lobular 510 66 0.79 0.62, 1.02 0.072 52 0.76 0.57, 1.01 0.062 96 0.92 0.75, 1.14 0.446
Mixed 364 52 0.92 0.69, 1.22 0.561 41 0.89 0.65, 1.22 0.456 59 0.82 0.63, 1.07 0.150
Others 389 66 2.32 1.54, 3.49 <0.001 55 2.92 1.79, 4.75 <0.001 87 2.01 1.44, 2.83 0.000
Histological grade              
1 499 35 1.00    23 1.00    55 1.00   
2 2,404 277 2.09 1.47, 2.97 <0.001 217 2.51 1.63, 3.87 <0.001 382 1.84 1.39, 2.45 <0.001
3 2,391 440 3.70 2.62, 5.23 <0.001 369 4.77 3.13, 7.28 <0.001 523 2.82 2.13, 3.72 <0.001
Unknown 389 66 2.32 1.54, 3.49 <0.001 55 2.92 1.79, 4.75 <0.001 87 2.01 1.44, 2.83 <0.001
Pathologic primary tumor size              
T1 2,794 249 1.00    194 1.00    349 1.00   
T2 2,665 510 1.96 1.68, 2.28 <0.001 417 2.03 1.71, 2.41 <0.001 628 1.78 1.57, 2.04 <0.001
T3 224 59 2.14 1.61, 2.84 <0.001 53 2.39 1.76, 3.25 <0.001 70 1.98 1.53, 2.57 <0.001
     P for trend <0.001    P for trend <0.001    P for trend <0.001
Estrogen receptor/progesterone receptor              
Both negative 1,502 300 1.00    256 1.00    349 1.00   
Any of them positive 4,132 503 0.49 0.43, 0.57 <0.001 394 0.45 0.38, 0.53 <0.001 679 0.59 0.51, 0.67 <0.001
Unknown 49 15 0.77 0.46, 1.31 0.338 14 0.82 0.48, 1.41 0.471 19 1.00 0.63, 1.59 0.998
Human epidermal growth factor-2 status              
Negative 4,055 518 1.00    407 1.00    660 1.00   
Positive 830 182 1.34 1.13, 1.59 0.001 153 1.42 1.18, 1.71 <0.001 223 1.38 1.18, 1.61 <0.001
Unknown 798 118 1.04 0.85, 1.28 0.690 104 1.17 0.94, 1 · 45 0.172 164 1.14 0.95, 1.36 0.157
Type of surgery              
Mastectomy 2,621 512 1.00    420 1.00    633 1.00   
Conservative 3,062 306 0.71 0.61, 0.82 <0.001 244 0.71 0.60, 0.83 <0.001 414 0.73 0.65, 0.83 <0.001
Hormonotherapy              
No 1,439 314 1.00    263 1.00    354 1.00   
Yes 4,045 451 0.42 0.36, 0.48 <0.001 356 0.39 0.33, 0.46 <0.001 622 0.51 0.45, 0.58 <0.001
Unknown 199 53 0.79 0.58, 1.06 0.112 45 0.77 0.56, 1.07 0.120 71 1.05 0.81, 1.37 0.692
Initial undertreatment (first dose <85%)              
No 5,532 648 1.00           
Yes 151 16 1.01 0.78,1.31 0.932 16 1.06 0.64, 1.75 0.820 20 0.84 0.54, 1.31 0.447
Overall undertreatment (dose <85%)              
None 5,083 725 1.00    599 1.00    943 1.00   
Epirubicine <85% 78 24 1.55 1.02, 2.36 0.040 20 1.56 0.98, 2.47 0.059 25 1.29 0.86, 1.93 0.226
Cyclophosphamide <85% 296 56 1.28 0.98, 1.69 0.074 41 1.13 0.82, 1.56 0.446 63 1.14 0.88, 1.47 0.323
Fluorouracil <85% 181 33 1.20 0.84, 1.70 0.316 23 1.01 0.66, 1.53 0.977 34 0.98 0.69, 1.38 0.888
Doxorubicin <85% 226 38 1.30 0.93, 1.81 0.119 27 1.12 0.76, 1.65 0.576 42 1.13 0.82, 1.54 0.451
Docetaxel <85% 176 32 1.08 0.74, 1.57 0.696 24 0.96 0.62, 1.47 0.846 39 1.04 0.74, 1.46 0.814
Paclitaxel <85% 244 27 1.43 0.94, 2.18 0.092 16 1.05 0.62, 1.78 0.863 30 1.09 0.74, 1.61 0.662
  1. aHazard ratio, 95% CI and P-value adjusted for study and treatment regimen.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us